Navigation Links
BELLUS Health reports results for the fourth quarter of 2008
Date:2/26/2009

and that it will initiate a second Phase III clinical trial for eprodisate (KIACTA(TM)) in close cooperation with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA). The Company expects to file the Investigational New Drug application (IND) in the first half of 2009, with approximately 190 patients to be followed for a period of 24 months. On April 15, 2008, the Company announced that it had regained full ownership rights and control of eprodisate (KIACTA(TM)) from Centocor. During the second quarter of 2008, the refundable portion ($6,000,000) of the upfront payment received from Centocor in 2005 was refunded to Centocor.

Research and development expenses, before research tax credits and grants, amounted to $3,916,000 for the current quarter ($25,027,000 for the year), compared to $12,199,000 for the same period the previous year ($55,732,000 for the year). The decrease in the current periods compared to the same periods the previous year is mainly attributable to a reduction in expenses incurred in relation to the development of tramiprosate (ALZHEMED(TM); homotaurine) for the treatment of AD, following the Company's decision in November 2007 to terminate the tramiprosate (ALZHEMED(TM)) pharmaceutical drug development program.

The Company is also developing NC-503 (eprodisate) for the treatment of Type II diabetes and certain features of metabolic syndrome. During the second quarter of 2008, a Phase II clinical trial in diabetic patients was initiated in Canada and patient recruitment and randomization commenced. The study is a randomized 26-week, double-blind, placebo-controlled study. Interim results are anticipated in early 2009. Results from a validated rat model of diabetes and metabolic syndrome have demonstrated that NC-503 decreases glycemic levels in obese diabetic Zucker rats, when compared to the control group, while preserving 40% more pancreatic islet cells (insulin secreting cells) as compared to the co
'/>"/>

SOURCE BELLUS HEALTH INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine news :

1. At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
2. BELLUS HEALTH reports results for first quarter of fiscal 2008
3. BELLUS Health to present at the Rodman and Renshaw 5th Annual Global Healthcare Conference
4. BELLUS Health announces closing of Innodia acquisition
5. BELLUS Health provides update on activities
6. BELLUS Health to present at the Rodman and Renshaw 10th Annual Healthcare Conference
7. BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update
8. BELLUS Health Announces Stock Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market
9. BELLUS Health is Preparing to Voluntarily Delist from the NASDAQ Capital Market
10. BELLUS Health announces formal notice to voluntarily delist from NASDAQ
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BELLUS Health Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... September 16, 2014 Recently, BuyTopDress.com, one ... has unveiled its new collection of elegant graduation ... these brand new items are on sale on the ... from 23 to 63 percent off. , These ... and design. They are available in a lot of ...
(Date:9/16/2014)... CA (PRWEB) September 16, 2014 Dr. ... the launch of ACLsurgeryLA.com , a specialty website ... injuries. As an avid sports lover and athlete, ... for treatment and recovery from injuries to maintain active, ... to offer patients a resource dedicated specifically to ...
(Date:9/16/2014)... 2014 MEDICC Review today ... genetics in Cuba. Although the articles do not ... are intrinsically connected, since cancers begin with errors in ... full spectrum of cancer control, from primary prevention to ... topic of an exclusive interview with National Medical ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Lambda Solutions, a ... systems , is excited to welcome Stewart Rogers ... Harvey, Sales Executive at Lambda Solutions comments, “Product leadership will ... right candidate to do so. Learning and talent management is ... changes to help clinical learning and talent development in the ...
(Date:9/16/2014)... Birmingham, Alabama (PRWEB) September 16, 2014 *To ... Birmingham, AL, visit Achieve Clinical Research on the web ( ... For those who qualify:, There is ... required , Compensation may be provided for ... stands, pneumonia and influenza are the eighth leading cause of ...
Breaking Medicine News(10 mins):Health News:Cheap Graduation Dresses Now Provided Online At BuyTopDress.com 2Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 2Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 3Health News:MEDICC Review Journal Dedicates Double Issue to Cancer and Genetics 2Health News:MEDICC Review Journal Dedicates Double Issue to Cancer and Genetics 3Health News:Stewart Rogers Joins Lambda Solutions as Director of Product Management 2Health News:Stewart Rogers Joins Lambda Solutions as Director of Product Management 3Health News:The Team at Achieve Clinical Research is Enrolling Qualified Individuals to Participate in a Pneumonia Vaccine Clinical Trial in Birmingham, Alabama 2Health News:The Team at Achieve Clinical Research is Enrolling Qualified Individuals to Participate in a Pneumonia Vaccine Clinical Trial in Birmingham, Alabama 3
... HealthDay Reporter , WEDNESDAY, Nov. 24 (HealthDay News) -- ... diagnosed until the disease is well-advanced and, therefore, less ... one-half of colorectal cancers and cervical cancers and one-third ... at a late stage, according to the report released ...
... WEDNESDAY, Nov. 24 (HealthDay News) -- A study conducted ... for blacks than it is for whites. In fact, ... one-fifth higher than it is for whites in that state. ... on Smoking and Health at the U.S. Centers for Disease ...
... London, UK, 24 November 2010 Research from ... ( http://www2.i-med.ac.at/psychlab/ ) at the Medical University Innsbruck ... in rats exhibited pathologies similar to Alzheimer,s disease. ... Neuroscience (45(4):408-417, 2010) with lead author Dr. ...
... holder of endowed chair during a research symposium at Children,s ... A. DeClerck, MD, professor of Pediatrics, Biochemistry and Molecular Biology ... Southern California has been inducted as the inaugural holder of ... "My family has long been dedicated to improving the ...
... 24 (HealthDay News) -- If you are one of the ... a few simple steps can help reduce your stress on ... School of Nursing at Binghamton University, State University of New ... items well ahead of time and have a list ready ...
... HealthDay Reporter , TUESDAY, Nov. 23 (HealthDay News) -- A ... 44 percent in those at highest risk for contracting the virus, ... finds. The reduction in risk climbed to nearly 73 percent ... of the time, the researchers added. Truvada is already available ...
Cached Medicine News:Health News:Too Many Cancers Still Spotted Too Late: CDC 2Health News:Too Many Cancers Still Spotted Too Late: CDC 3Health News:Black Smokers May Face Higher Death Risk Than Whites: CDC 2Health News:Chronic high cholesterol diet produces brain damage 2Health News:Richard Call Family Endowed Chair honors Dr. Yves DeClerck at the Saban Research Institute Symposium 2Health News:Daily Pill Lowers Odds for Infection With HIV 2Health News:Daily Pill Lowers Odds for Infection With HIV 3Health News:Daily Pill Lowers Odds for Infection With HIV 4
(Date:9/16/2014)... NEW PROVIDENCE, N.J. , Sept. 16, 2014 /PRNewswire/ ... paper on the critical elements of installing and maintaining ... systems at the American Society of Plumbing Engineers Convention ... Chicago Sheraton Hotel and Towers in Chicago ... , program manager of Hospital Services for Linde Healthcare, ...
(Date:9/15/2014)... NEW YORK , Sept. 16, 2014 ... the Hereditary Neuropathy Foundation (HNF) announced today an agreement ... Charcot-Marie-Tooth (CMT) disease and support the development of a ... Pharnext will provide financial support to several HNF,s initiatives ... a specific section in the HNF website featuring  HNF ...
(Date:9/15/2014)... 15, 2014 /CNW/ - Health Minister Rona Ambrose ... available for donation over $2.5 million in personal protective equipment ... the global response to the Ebola outbreak in ... a shortage of equipment in the affected countries and has ... workers in the affected countries. Personal protective ...
Breaking Medicine Technology:Linde Healthcare experts to present details on installation of medical oxygen storage and distribution systems at ASPE convention 2Linde Healthcare experts to present details on installation of medical oxygen storage and distribution systems at ASPE convention 3Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 2Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 3Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 4Canada offers essential protective equipment to help stop the spread of Ebola in West Africa 2Canada offers essential protective equipment to help stop the spread of Ebola in West Africa 3
... Pharmaceuticals, Inc. (NYSE Amex: ANX ) today announced ... offer and sell shares of its common stock and warrants ...  The Company also intends to grant the underwriters a 45-day ... shares and warrants sold in the public offering to cover ...
... Food and Drug Administration has licensed HEMACORD™ (Hematopoietic ... cell transplantation, the first such approval of a ... According to the Food and Drug Administration,s ... is "indicated for use in unrelated donor hematopoietic ...
Cached Medicine Technology:ADVENTRX Announces Public Offering of Stock 2ADVENTRX Announces Public Offering of Stock 3FDA Approves New York Blood Center's HEMACORD™ for Stem Cell Transplantation 2FDA Approves New York Blood Center's HEMACORD™ for Stem Cell Transplantation 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: